All news

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

(Image: Getty/Gajus)

Hired and Retired: Pharma C-suites see new faces

By Maggie Lynch

While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.

Follow us

Products

View more

Webinars